We present a 62-year-old female who collapsed with a subarachnoid haemorrhage. This was complicated by profound shock secondary to neurogenic stunned myocardium. As the patient demonstrated life-threatening catecholamine-resistant shock that was unresponsive to conventional treatment measures, hyperinsulinaemic euglycaemic therapy was utilised as a rescue therapy. To our knowledge this has not previously been described in the literature. The patient proceeded to stabilise and made a good recovery.
A subarachnoid haemorrhage (SAH) occurs when there is a sudden leakage of blood below the arachnoid covering of the brain. Intracranial aneurysms remain the most common cause. SAH presents with a range of symptoms including a classical sudden-onset headache, loss of consciousness, seizures and cardiovascular instability. It has a mortality rate of around 50% including pre-hospital deaths. Serious cardiovascular complications of SAH include left ventricular impairment and neurogenic pulmonary oedema which may be related to a dramatic increase in endogenous catecholamines following the acute event. Conventional management of cardiovascular instability following SAH involves the use of inotropes and vasopressors to maintain organ perfusion. Catecholamines may be ineffective in neurogenic stunned myocardium, and side-effects are undesirable. Hyperinsulinaemic euglycaemic therapy may help to improve cardiac function by offsetting the intracellular metabolic dysregulation in cardiomyocytes.
Case History
A previously well 62-year-old female holidaymaker (body mass index 32 kg/m 2 ) presented overnight to our emergency department (ED) following a collapse and seizure. Prior to this she had complained of a severe headache. Initial Glasgow Coma Scale (GCS) score on arrival to the hospital was three, but subsequently increased to ten in the ED. Her initial observations showed that she was markedly hypoxic, hypertensive and tachycardic (oxygen saturation 84%, blood pressure 198/126 mmHg, heart rate 151 per minute). Due to the severity of her hypoxia, fluctuant GCS and agitation, it was decided that she would require sedation for mechanical ventilation via an artificial airway to have a computed tomography (CT) brain scan performed safely. A rapid sequence induction with intubation was undertaken, using intravenous propofol (200 mg), alfentanil (1 mg) and suxamethonium (100 mg). Following administration of induction drugs, her blood pressure fell to an unrecordable level, and she required cardiopulmonary resuscitation (including adrenaline 1 mg and four minutes of chest compressions) to restore spontaneous circulation, but her blood pressure response to vasopressor infusions remained unsatisfactory.
The CT brain scan showed a disseminated SAH, with blood visible in the fourth ventricle and signs of early hydrocephalus (modified Fisher grade IV). Following discussion with the neurosurgical team in our local tertiary referral centre, it was agreed that she was too unstable to be transferred to the nearest neurosurgical intensive care unit (ICU) by a 60-minute road transfer and should be stabilised first in our general ICU. Ventilation and sedation were optimised to limit intracranial pressure and maintain cerebral perfusion pressure; enteral nimodipine was administered as per neurosurgical advice. Her gas exchange and ventilation were severely impaired; she required 100% inspired oxygen and a positive endexpiratory pressure of 12 cmH 2 O to maintain oxygenation (PaO 2 /FiO 2 95.3 mmHg). Her cardiovascular system remained unstable and at four hours post admission to ICU, she was requiring norepinephrine (noradrenaline) at 0.56 μg/kg/ minute to maintain a mean arterial pressure around 75-80 mmHg. Her urine output had started to fall, and her arterial lactate levels were showing an upward trend, suggesting the onset of multi-organ failure. Chest X-ray showed features of pulmonary oedema and a 12-lead electrocardiogram (ECG) showed sinus tachycardia. . Dobutamine infusion was commenced, but due to exacerbation of her pre-existing tachycardia (heart rate of 125 /minute), the dose was limited to a maximum of 2.5 μg/kg/minute. Intravenous hydrocortisone (200 mg followed by 50 mg six-hourly) was started for its potential catecholamine-sparing effect, and intravenous calcium gluconate was also given.
By ten hours after ICU admission, the norepinephrine requirement had almost doubled (0.9 μg/kg/minute). The arterial lactate concentrations continued to increase (peaking at 6.2 mmol/l), and the patient was becoming increasingly acidotic with a pH of 7.25, with persistent oliguria and elevated plasma urea and creatinine concentrations consistent with acute kidney injury (AKI) (Kidney Disease: Improving Global Outcomes grade 1). She remained hypoxic and required a high inspired oxygen concentration (95%, PaO 2 /FiO 2 106.5 mmHg). The serum troponin obtained at ten hours after ICU admission was high (10.378 μg/l). With her deteriorating haemodynamic status resistant to catecholamine infusions, we decided to introduce hyperinsulinaemic euglycaemic therapy (HET). An insulin infusion was started at 60 units/hour, simultaneously with 50% dextrose infusion at 50 ml/hour. Within one hour, the CO had risen to 6.4 litres per minute and the SV to 54 ml (cardiac index 3 l/min/m 2 ). By 15 hours after ICU admission, we were able to reduce the norepinephrine dose to 0.76 μg/kg/ minute with a reduction in arterial lactate concentrations to 2.8 mmol/l and a higher pH of 7.32. Her AKI and oxygenation both started to improve (PaO 2 /FiO 2 165.0 mmHg). At this point, insulin was running at 40 units/hour. Her blood glucose concentrations were maintained between 4 and 10 mmol/l by continuing the 50% dextrose infusion, and her potassium levels were maintained between 3.5 and 4.5 mmol/l with a potassium infusion.
At 32 hours after admission, the patient had stabilised, with improvements in her cardiac, respiratory and renal systems. Formal echocardiography showed the left ventricular function had improved with only mild impairment (ejection fraction of 45%), but complex regional wall motion abnormalities persisted. Over the next few hours the HET infusions were weaned, and sedation was ceased. The patient was able to obey simple commands with no focal neurological deficits. Following further discussion with the local neurosurgical team, the patient was transferred to our local tertiary neurosurgical centre where her cerebral aneurysm was embolised with coils, and mechanical ventilation was subsequently successfully removed. After a period of rehabilitation, the patient was eventually discharged home without long-term neurological deficit.
Discussion
Neurogenic stunned myocardium (NSM) is recognised as a combination of cardiogenic shock, pulmonary oedema, metabolic acidosis, left ventricular wall motion abnormalities and ECG changes (T wave inversion, Q waves) occurring after a severe neurological injury. It has been associated with high-grade SAH and female sex 1 . The predominant theory for the underlying pathophysiology is that SAH triggers a massive release of endogenous catecholamines, which can persist for seven to ten days 2 . This massive elevation in catecholamines can result in subendocardial band necrosis, and catecholamine-resistant shock.
NSM following SAH is generally a transient state, but supportive management may prove difficult. Inotropic agents such as dobutamine may worsen pre-existing tachyarrhythmias, and vasopressors may be ineffective in the face of high endogenous catecholamine levels. A study comparing milrinone and dobutamine in SAH patients with pulmonary artery catheter monitoring suggested that milrinone was more effective at increasing cardiac output, but it was associated with more hypotension 3 . It is likely that there is a significant overlap in terms of pathophysiology and presentation between NSM and Takotsubo cardiomyopathy, with each a form of stress-induced cardiomyopathy 4 . Numerous publications have described an association between catecholamine infusions and stress-induced cardiomyopathy 5, 6 , which may indicate why catecholamines were ineffective in our patient. The dose of dobutamine we used was very low (less than the usual doses used in the cardiogenic shock setting, typically in the range of 3-15 μg/ kg/minute), but this was primarily due to extreme tachycardia at the time.
The use of a glucose, insulin and potassium infusion in myocardial ischaemia was first described in 1961. The term 'euglycaemic clamp' is generally used to describe metabolic studies using a similar technique. Over the last 20 years numerous descriptions of HET have been published. Most descriptions of HET consist of a high dose insulin infusion (in the range of 0.5-1 unit/kg/hour) combined with infusions of glucose and potassium to avoid hypoglycaemia and hypokalaemia, respectively. The use of HET has been extensively reported as a treatment for hypotension resulting from overdose of calcium channel and beta-blocker drugs. In both of these settings, there is a combination of hypotension and resistance to catecholamine infusions. HET has previously been described as an inotropic therapy for low cardiac output following a SAH, but not as a rescue therapy as in this case 7, 8 . Cardiomyocytes are able to metabolise both free fatty acids (FFA) and glucose. In healthy cardiomyocytes, the metabolism of FFA yields more adenosine triphosphate (ATP) than aerobic glycolysis (1 mol of palmitate yields 108 mol ATP versus 38 mol ATP from oxidative glycolysis). FFA are therefore the cardiomyocytes' preferred energy source. The higher yield of ATP from FFA metabolism comes at a cost of increased cellular oxygen requirements 9 . Glucose and FFA compete as energy sources and exert a negative feedback on each other; thus metabolism of FFA will tend to impair the use of glucose and vice versa. During periods of stress or ischaemia, the cardiomyocytes' preferred energy source is glucose, but glucose metabolism is impaired by FFA. This situation may be worsened by activation of the sympathetic nervous system or the use of catecholamine infusions that increase lipolysis and result in more uptake of FFA into the heart. The use of insulin aims to transfer more glucose into the cardiomyocytes, and also impairs the further breakdown of FFA, improving the energy balance within the cell 10 .
In canine studies with heart failure and stress, it was found that there is an increase in insulin resistance secondary to increased FFA and also increased renin-angiotensinaldosterone system activation causing further aggravation of heart failure 10 . Even though glucose is the preferred substrate in this situation, this adaptation is inhibited by high insulin resistance. Using high-dose inotropes will cause increased insulin resistance, decreased insulin secretion, increased FFA and lactate production and hyperglycaemia 11 . The timing of initiation of HET in relation to our patient's clinical improvements suggests that HET may have a role to play in reversing some of this metabolic dysregulation within the failing heart in the context of high endogenous and exogenous catecholamine levels.
There are potential risks of HET, including hyper-and hypoglycaemia, alongside electrolyte abnormalities, all of which could have significant implications, especially in the setting of an acutely injured brain with a failing heart (e.g. atrial fibrillation). We recognise that the nature of NSM is typically a transient response, and that other factors would have inevitably been contributing to our patient's cardiovascular failure. In our case all other available treatment measures were either ineffective or potentially worsening the situation. It was only following the introduction of HET that her condition stabilised, which was achieved without any significant side-effects. Within many institutions treatment options may be limited by availability and expertise, and thus, utilising common agents in a relatively novel way as a rescue therapy seemed appropriate in our patient.
Conclusions
Our case demonstrates the use of HET as a rescue therapy in the context of severe neurogenic myocardial stunning with tachycardia refractory to high dose norepinephrine. HET is cheap and relatively easy to administer. In an isolated general ICU, with limited access to other forms of advanced cardiovascular support for the failing heart such as venoarterial extracorporeal membrane oxygenation, it may represent a useful alternative therapy in selected cases of NSM. Based on our observations in this case, we would suggest this may represent an area of interest for further study.
This case report was compiled after the patient's written consent was obtained.
